Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 18, 2015 3:47 PM ET


Company Overview of 3SBio Inc.

Company Overview

3SBio Inc. offers research and development, manufacture, and marketing of bio-pharmaceutical products. Its principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombocytopenia. The company also markets Intefen, a recombinant interferon alpha-2a product to treat carcinoma and viral infectious diseases; Inleusin, a recombinant human interleukin-2 product to treat renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused by cancer and tuberculosis; Iron Su...

No. 3 A1, Road 10

Shenyang Economy & Technology Development Zone

Shenyang,  110027


Founded in 2006

891 Employees


86 24 2538 6000

Key Executives for 3SBio Inc.

Co-Founder, Chairman, Chief Executive Officer, Chairman of Nominating Committee and Member of Investment Committee
Age: 51
Co Founder and Advisor
Age: 78
Chief Financial Officer, Principal Accounting Officer and Member of Investment Committee
Age: 41
Chief Technology Officer, Vice President of R&D and Director
Age: 44
Vice President and Corporate Secretary
Age: 46
Compensation as of Fiscal Year 2014.

3SBio Inc. Key Developments

3SBio Signs Exclusive Patent License Agreement for DIG-KT With PharmAbcine, Inc

3SBio Inc. announced that it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody (mAb) targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

3SBio Signs License Agreement with Jenkem Technology

3SBio Inc. has signed an exclusive license agreement with JenKem Technology Co. Ltd. The contract has been signed for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate that inhibits topoisomerase I (Topo-I). Researchers from JenKem produced PEG-irinotecan to treat Topo-I over-expressed cancers. JenKem's PEG-irinotecan indicated significant effects on tumour repression and toxicity in several in vivo tumour models, suggesting it is likely to have the potential to suppress tumour growth throughout the entire chemotherapy cycle.

3SBio Inc. Signs Exclusive Patent License Agreement with DiNonA Inc. for Leukotuximab

3SBio Inc. announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey). In addition to an upfront payment, milestone payments will be made after completion of technology transfer, approval of Investigational New Drug (IND) application by the China Food and Drug Administration (CFDA), completions of Phase I to Phase III clinical trials and marketing approval in China. 3SBio will also pay DiNonA a sales-based royalty. Additional terms of the license are not being disclosed. The incidence rate for AML is 1.6 per 100,000 annually; the incidence rate for ALL is 0.4 per 100,000 annually. In China, there are about two to three million existing AL patients. Among them, between 30,000 and 40,000 patients are newly diagnosed each year. Patients are currently treated with traditional chemotherapy and bone marrow transplant, both of which have major side effects. Researchers from DiNonA have developed Leukotuximab, an anti-leukemic agent for JL-1+ acute leukemia. This antibody is targeting JL-1 Ag, an epitope of human CD43 extracellular domain. JL-1 is expressed on tumor cells of T, B, and myeloid lineages in more than 80% of acute leukemia patients, but not on mature peripheral blood cells or other normal tissues. Since the expression of JL-1 is highly associated with hematopoietic malignancies and is selectively expressed on the surface of human leukemic cells, anti-JL-1 mAb can be an excellent targeted reagent for treatment of the leukemia. Leukotuximab showed significant improvement in survival in leukemia animal models. Also, no evidence of toxicity was observed in study animals. An open label and dose-escalating Phase I clinical trial in Korea started at June 2014 and is expected to finish in late 2015.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 3SBio Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at